Cowen restated their outperform rating on shares of CVS Health (NYSE:CVS) in a report released on Thursday morning, The Fly reports. Cowen currently has a $99.00 target price on the pharmacy operator’s stock, up from their prior target price of $81.00.
Other research analysts have also recently issued reports about the company. ValuEngine cut CVS Health from a buy rating to a hold rating in a research note on Sunday, December 31st. Robert W. Baird reiterated a hold rating and set a $77.00 price target on shares of CVS Health in a research report on Friday, October 27th. Mizuho set a $90.00 price target on CVS Health and gave the company a buy rating in a research report on Tuesday, October 24th. Leerink Swann lifted their price target on CVS Health from $82.00 to $90.00 and gave the company an outperform rating in a research report on Monday, January 8th. Finally, Vetr cut CVS Health from a hold rating to a sell rating and set a $76.66 price target for the company. in a research report on Tuesday, January 16th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company. The stock currently has an average rating of Buy and an average target price of $87.25.
Shares of CVS Health (NYSE:CVS) traded up $0.51 during trading hours on Thursday, hitting $79.86. The stock had a trading volume of 7,944,833 shares, compared to its average volume of 8,930,000. CVS Health has a 1 year low of $66.45 and a 1 year high of $84.00. The stock has a market capitalization of $80,900.00, a PE ratio of 16.50, a price-to-earnings-growth ratio of 1.26 and a beta of 0.90. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.55 and a current ratio of 1.05.
CVS Health (NYSE:CVS) last announced its quarterly earnings data on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.01. CVS Health had a return on equity of 16.96% and a net margin of 2.77%. The firm had revenue of $46.18 billion during the quarter, compared to analysts’ expectations of $46.17 billion. During the same period last year, the business posted $1.64 earnings per share. The company’s revenue for the quarter was up 3.5% compared to the same quarter last year. research analysts expect that CVS Health will post 5.89 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 2nd. Stockholders of record on Wednesday, January 24th will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.50%. The ex-dividend date of this dividend is Tuesday, January 23rd. CVS Health’s dividend payout ratio (DPR) is presently 41.32%.
In other news, EVP Lisa Bisaccia sold 29,445 shares of the business’s stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $75.00, for a total value of $2,208,375.00. Following the completion of the sale, the executive vice president now directly owns 15,556 shares in the company, valued at $1,166,700. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.61% of the stock is owned by insiders.
Several institutional investors have recently bought and sold shares of CVS. FMR LLC boosted its stake in shares of CVS Health by 22.0% in the second quarter. FMR LLC now owns 30,150,634 shares of the pharmacy operator’s stock worth $2,425,920,000 after acquiring an additional 5,446,930 shares during the last quarter. Truepoint Inc. boosted its stake in shares of CVS Health by 8,578.9% in the third quarter. Truepoint Inc. now owns 3,757,530 shares of the pharmacy operator’s stock worth $3,758,000 after acquiring an additional 3,714,235 shares during the last quarter. Boston Partners boosted its stake in shares of CVS Health by 69.1% in the second quarter. Boston Partners now owns 6,459,237 shares of the pharmacy operator’s stock worth $519,711,000 after acquiring an additional 2,638,888 shares during the last quarter. Ameriprise Financial Inc. boosted its stake in shares of CVS Health by 30.2% in the third quarter. Ameriprise Financial Inc. now owns 7,977,370 shares of the pharmacy operator’s stock worth $648,683,000 after acquiring an additional 1,849,593 shares during the last quarter. Finally, Parametric Portfolio Associates LLC boosted its stake in shares of CVS Health by 71.5% in the second quarter. Parametric Portfolio Associates LLC now owns 3,949,854 shares of the pharmacy operator’s stock worth $317,805,000 after acquiring an additional 1,647,168 shares during the last quarter. Institutional investors and hedge funds own 81.69% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.thelincolnianonline.com/2018/01/21/cvs-health-cvs-earns-outperform-rating-from-cowen.html.
About CVS Health
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.